Showing results (691-700 of 746) with videos related to
Sort By:
Pageof 75
The New England Journal of Medicine|January 24, 2014
PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphomaAjay K Gopal, Brad S Kahl, Sven de Vos, et al.Medrxiv : the Preprint Server for Health Sciences|November 21, 2023
Associations between regional adipose tissue distribution and skeletal muscle bioenergetics in older men and womenAndrea M Brennan, Paul M Coen, Theresa Mau, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2018
Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal TrialStephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 2022
Zanubrutinib Versus Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma: Interim Analysis of a Randomized Phase III TrialPeter Hillmen, Barbara Eichhorst, Jennifer R Brown, et al.Leukemia|September 25, 2024
Epcoritamab in relapsed/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trialCatherine Thieblemont, Yasmin H Karimi, Herve Ghesquieres, et al.Obesity (Silver Spring, Md.)|May 28, 2024
Associations between regional adipose tissue distribution and skeletal muscle bioenergetics in older men and womenAndrea M Brennan, Paul M Coen, Theresa Mau, et al.Blood|January 15, 2016
Postibrutinib outcomes in patients with mantle cell lymphomaPeter Martin, Kami Maddocks, John P Leonard, et al.Lancet (London, England)|December 16, 2017
Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trialMichael Wang, Simon Rule, Pier Luigi Zinzani, et al.Communications Chemistry|August 15, 2025
Targeted degradation of GSPT1 and NEK7 by a molecular glue prodrug for treatment of HCCPrzemysław Glaza, Roman Pluta, Krzysztofa E Odrzywół, et al.The New England Journal of Medicine|December 13, 2022
Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic LeukemiaJennifer R Brown, Barbara Eichhorst, Peter Hillmen, et al.Pageof 75